Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, the Netherlands; Department of Clinical Epidemiology and Medical Technology Assessment, CAPHRI Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, the Netherlands.
Division of Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, the Netherlands.
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2628-2637. doi: 10.1016/j.cgh.2022.02.016. Epub 2022 Feb 16.
BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is a highly prevalent, chronic disorder of the gut-brain interaction that significantly affects quality of life. Several treatments, with comparable clinical efficacy, are available. Patient preferences can therefore be an important determinant of an effective management strategy. Treatment preferences of patients regarding decision making remain unclear. We aimed to examine these preferences and estimate trade-offs between different attributes.
A total of 427 patients from the Maastricht IBS cohort were invited to participate. A labeled discrete choice experiment survey, containing 9 scenarios with each 3 alternatives (medication, diet, psychotherapy), was developed in order to estimate preferences. The treatment scenarios were based on 6 attributes: effectiveness, time to response, time until recurrence, side effects, time required, and frequency of appointments. The preference weights and relative importance were analyzed using a mixed logit model.
A total of 185 (43.3%) of 427 potential respondents completed the questionnaire (mean age 49.51 years, 69.2% female). The most preferred treatment was dietary intervention (48.1%), followed by pharmacotherapy (29.2%) and psychotherapy (22.7%). IBS patients preferred a higher effectiveness, shorter time interval to response, longer time interval until recurrence, no severe side effects, and frequent appointments when attending psychotherapy. Younger patients (≤50 years of age) preferred dietary interventions and a long period until recurrence, whereas older patients (>50 years of age) were more inclined to choose pharmacotherapy and the period until recurrence was not important.
Dietary interventions were the most preferred IBS therapy. Identifying patients' treatment preferences during shared decision making will provide more optimal management strategies and could be the best approach to diminish disease burden.
肠易激综合征(IBS)是一种高发的、慢性的胃肠道-大脑相互作用紊乱,严重影响生活质量。目前有几种疗效相当的治疗方法。因此,患者的偏好可能是有效治疗策略的一个重要决定因素。关于决策,患者的治疗偏好仍不清楚。本研究旨在调查这些偏好,并评估不同属性之间的权衡取舍。
我们邀请了马斯特里赫特 IBS 队列中的 427 名患者参与研究。设计了一个包含 9 个场景的标记离散选择实验调查,每个场景有 3 个选择(药物治疗、饮食治疗、心理治疗),以评估患者的偏好。治疗方案基于 6 个属性:疗效、起效时间、复发时间、副作用、所需时间和就诊频率。使用混合 logit 模型分析偏好权重和相对重要性。
共有 427 名潜在受访者中的 185 名(43.3%)完成了问卷调查(平均年龄 49.51 岁,69.2%为女性)。最受欢迎的治疗方法是饮食干预(48.1%),其次是药物治疗(29.2%)和心理治疗(22.7%)。IBS 患者更喜欢高疗效、起效时间短、复发时间长、无严重副作用和心理治疗的频繁就诊。年龄较小(≤50 岁)的患者更喜欢饮食干预和较长的复发时间,而年龄较大(>50 岁)的患者更倾向于选择药物治疗,复发时间并不重要。
饮食干预是最受欢迎的 IBS 治疗方法。在共同决策中确定患者的治疗偏好将提供更优化的管理策略,可能是减轻疾病负担的最佳方法。